Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB and Amgen announce positive data from osteoporosis drug trial

UCB and Amgen announce positive data from osteoporosis drug trial

10th September 2015

UCB and Amgen have announced new clinical trial data showing the benefits offered by romosozumab in the treatment of osteoporosis.

Top-line results from the STRUCTURE trial demonstrated a statistically significant difference in favour of romosozumab, when compared to an older therapy, in the percent change of total hip bone mineral density after 12 months, thus meeting the primary endpoint.

Meanwhile, the overall subject incidence of adverse events was generally balanced between arms, with adverse events in patients treated with romosozumab shown to be similar to those previously reported. No new safety signals were detected.

The study was a phase III trial evaluating the safety, tolerability and efficacy of romosozumab in women with postmenopausal osteoporosis, with a total of 436 patients being enrolled.

Further analysis of the STRUCTURE study results are ongoing and will be submitted to a future medical conference and for publication, UCB confirmed.

Romosozumab is being studied for its potential to reduce the risk of fractures in an extensive global phase III programme, including two large fracture trials involving more than 10,000 postmenopausal women with osteoporosis.ADNFCR-8000103-ID-801800108-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.